{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:30:45Z","timestamp":1793705445071,"version":"4.5.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jacc.2018.09.052","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T16:41:54Z","timestamp":1543855314000},"page":"2886-2903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"PA","title":["Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome"],"prefix":"10.1016","volume":"72","author":[{"given":"Guglielmo","family":"Gallone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeem","family":"Latib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.09.052_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM198610163151602","article-title":"Platelet activation in unstable coronary disease","volume":"315","author":"Fitzgerald","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib3","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2016.03.485","article-title":"DAPT score utility for risk prediction in patients with or without previous myocardial infarction","volume":"67","author":"Kereiakes","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after pci with drug-eluting stents risk scores from Paris","volume":"67","author":"Baber","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib6","first-page":"e38","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0735-1097(03)00920-3","article-title":"The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction","volume":"42","author":"Kernis","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1161\/hc3601.095717","volume":"104","author":"Hudson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9149(93)91100-V","article-title":"Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction","volume":"72","author":"Kornowski","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib10","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199005313222201","article-title":"Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction","volume":"322","author":"Trip","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib11","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study)","volume":"31","author":"Fox","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a\u00a0long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.amjmed.2014.12.007","article-title":"Late consequences of acute coronary syndromes: Global registry of acute coronary events (GRACE) follow-up","volume":"128","author":"Alnasser","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jcin.2016.11.047","article-title":"Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta-analysis of randomized trials","volume":"10","author":"Elgendy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.052_bib15","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJMoa1701067","article-title":"Fractional flow reserve\u2013guided multivessel angioplasty in myocardial infarction","volume":"376","author":"Smits","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(15)60648-1","article-title":"Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3\u2014PRIMULTI): an open-label, randomised controlled trial","volume":"386","author":"Engstr\u00f8m","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacc.2018.09.052_bib17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jacc.2014.12.038","article-title":"Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for stemi and multivessel disease: The CvLPRIT trial","volume":"65","author":"Gershlick","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.113.001803","article-title":"Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score","volume":"128","author":"Farooq","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.jacc.2012.03.010","article-title":"Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: The residual SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score","volume":"59","author":"G\u00e9n\u00e9reux","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib20","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/01.CIR.0000087481.55887.C9","article-title":"From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jacc.2014.11.041","article-title":"The myth of the \u201cvulnerable plaque\u201d: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment","volume":"65","author":"Arbab-Zadeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCULATIONAHA.109.891523","article-title":"Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes","volume":"121","author":"Chow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib23","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.09.052_bib26","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib27","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib29","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib32","first-page":"1","article-title":"2017 ESC\u00a0guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","author":"Ibanez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib33","first-page":"1","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","author":"Valgimigli","year":"2017","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"10.1016\/j.jacc.2018.09.052_bib34","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib35","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib36","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib37","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib38","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib39","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.111.047431","article-title":"Acute coronary events","volume":"125","author":"Arbab-Zadeh","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib40","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2009.07.078","article-title":"The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization","volume":"55","author":"Kubo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib41","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/01.CIR.0000025609.13806.31","article-title":"Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study","volume":"106","author":"Rioufol","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/hrt.82.3.265","article-title":"Mechanisms of progression in native coronary artery disease: role of healed plaque disruption","volume":"82","author":"Mann","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2018.09.052_bib43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/01.CIR.103.7.934","article-title":"Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression","volume":"103","author":"Burke","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MCA.0000000000000279","article-title":"Natural history of coronary atherosclerosis","volume":"26","author":"Ain","year":"2015","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jacc.2018.09.052_bib45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib46","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib47","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","article-title":"Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010","volume":"5","author":"Smolina","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2018.09.052_bib48","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib49","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2017.02.050","article-title":"Incident myocardial infarction and very late stent thrombosis in outpatients with stable coronary artery disease","volume":"69","author":"Lemesle","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib50","first-page":"1","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"6736","author":"Connolly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0180010","article-title":"Long term health outcomes in patients with a history of myocardial infarction: a population based cohort study","volume":"12","author":"Tangri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.09.052_bib52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1185\/03007995.2015.1136607","article-title":"Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population","volume":"32","author":"Kern","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2018.09.052_bib53","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A\u00a0randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib54","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib55","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib56","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: The IVUS-XPL Randomized Clinical Trial","volume":"9","author":"Hong","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.052_bib57","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- Versus 12-month dual antiplatelet therapy","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience\/Promus versus Cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib59","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12\u00a0months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib60","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: The reset trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib61","first-page":"2510","article-title":"Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib62","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A\u00a0prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib63","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.09.052_bib64","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA Trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib65","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/eurheartj\/ehv038","article-title":"Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After","volume":"36","author":"Costa","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib66","first-page":"1","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","author":"Udell J a","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib67","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib68","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib69","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib70","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib71","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib73","doi-asserted-by":"crossref","first-page":"B84","DOI":"10.1016\/j.jacc.2016.09.258","article-title":"Extended validation of a decision tool (DAPT score) in patients randomized to 6 or 12\u00a0months dual antiplatelet therapy after percutaneous coronary\u00a0intervention with predominantly second-generation drug-eluting stents","volume":"68","author":"Harada","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib74","doi-asserted-by":"crossref","first-page":"e002524","DOI":"10.1161\/JAHA.115.002524","article-title":"Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy","volume":"4","author":"Costa","year":"2015","journal-title":"J.\u00a0Am. Heart Assoc"},{"key":"10.1016\/j.jacc.2018.09.052_bib75","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib76","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y 12 -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib77","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib78","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib79","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A\u00a0randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib80","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib81","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib82","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","article-title":"High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study","volume":"129","author":"Montalescot","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib83","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE Trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib84","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","volume":"53","author":"Jeong","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib85","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/hrt.2010.216499","article-title":"Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial","volume":"97","author":"Park","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2018.09.052_bib86","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":"Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib87","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib88","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"THE PRESENT AND FUTURE Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib89","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib90","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib91","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000442706","article-title":"Clopidogrel use as single antiplatelet therapy in outpatients with stable coronary artery disease: prevalence, correlates and association with prognosis (from the CORONOR Study)","volume":"134","author":"Lemesle","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2018.09.052_bib93","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of\u00a0adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib94","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib95","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib96","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib97","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00228-015-1917-9","article-title":"Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study","volume":"71","author":"Collet","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2018.09.052_bib98","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib101","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib102","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib103","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Trialists","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib104","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Treatment","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib105","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.052_bib106","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2018.09.052_bib107","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib108","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib109","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib110","first-page":"1","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"6736","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib111","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am. Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib112","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib113","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"History of discovery: inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.09.052_bib114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199408183310701","article-title":"The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina","volume":"331","author":"Liuzzo","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib117","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/eurheartj\/ehr310","article-title":"Creating controversy where none exists: The important role of C-reactive protein in the CARE, AFCAPS\/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials","volume":"33","author":"Braunwald","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib119","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/ATVBAHA.113.301925","article-title":"Regulation of an inflammatory disease: Kr\u00fcppel-like factors and atherosclerosis","volume":"34","author":"Jain","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2018.09.052_bib120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","article-title":"Pleiotropic effects of statin therapy: molecular mechanisms and clinical results","volume":"14","author":"Wang","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib121","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib122","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib123","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity c-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib124","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib126","doi-asserted-by":"crossref","first-page":"e005934","DOI":"10.1161\/CIRCIMAGING.116.005934","article-title":"Relationship between serum inflammatory marker levels and the dynamic changes in coronary plaque characteristics after statin therapy","volume":"10","author":"Kwon","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2018.09.052_bib127","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2011.03.044","article-title":"Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography","volume":"58","author":"Folco","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib129","first-page":"1","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"6736","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2018.09.052_bib131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib132","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk)","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.052_bib133","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.052_bib134","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"Harrington","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib136","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib139","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamacardio.2017.2249","article-title":"Optimal medical therapy for known coronary artery disease: a review","volume":"2","author":"Gibbons","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on\u00a0the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jacc.2018.09.052_bib141","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2014findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2018.09.052_bib142","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib143","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.05.063","article-title":"Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction","volume":"70","author":"Magnuson","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib144","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib145","unstructured":"Lamy A. Cost impact of rivaroxaban plus aspirin versus aspirin in the COMPASS trial. Paper presented at: American Heart Association 2017 Congress; November 14, 2017; Anaheim, California."},{"key":"10.1016\/j.jacc.2018.09.052_bib146","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","article-title":"Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective","volume":"270","author":"Ademi","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib147","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal\u00a0hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.052_bib148","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for\u00a0atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.052_bib149","first-page":"801","article-title":"Superficial erosion and the precision management of acute coronary syndromes: not one-size-fits-all","volume":"38","author":"Libby","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOL.0000000000000440","article-title":"Mechanisms of erosion of atherosclerotic plaques","volume":"28","author":"Quillard","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2018.09.052_bib151","first-page":"792","article-title":"Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSIONstudy)","volume":"38","author":"Jia","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.052_bib152","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1253\/circj.CJ-17-1373","article-title":"Optical coherence tomography guidance in management of acute coronary syndrome caused by plaque erosion","volume":"82","author":"Jia","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2018.09.052_bib153","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/eurheartj\/ehx786","article-title":"Plaque erosion: a new in\u00a0vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes","volume":"39","author":"Partida","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718387187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718387187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:17:58Z","timestamp":1760015878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718387187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":150,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0735109718387187"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.09.052","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.09.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}